KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Total Liabilities (2016 - 2026)

NovoCure's Total Liabilities history spans 13 years, with the latest figure at $457.2 million for Q1 2026.

  • On a quarterly basis, Total Liabilities fell 48.45% to $457.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $457.2 million, a 48.45% decrease, with the full-year FY2025 number at $463.9 million, down 47.32% from a year prior.
  • Total Liabilities hit $457.2 million in Q1 2026 for NovoCure, down from $463.9 million in the prior quarter.
  • Over the last five years, Total Liabilities for NVCR hit a ceiling of $1.0 billion in Q3 2025 and a floor of $457.2 million in Q1 2026.
  • Historically, Total Liabilities has averaged $765.6 million across 5 years, with a median of $752.6 million in 2023.
  • Biggest five-year swings in Total Liabilities: rose 18.42% in 2025 and later tumbled 48.45% in 2026.
  • Tracing NVCR's Total Liabilities over 5 years: stood at $750.5 million in 2022, then rose by 4.42% to $783.6 million in 2023, then rose by 12.37% to $880.6 million in 2024, then tumbled by 47.32% to $463.9 million in 2025, then dropped by 1.43% to $457.2 million in 2026.
  • Business Quant data shows Total Liabilities for NVCR at $457.2 million in Q1 2026, $463.9 million in Q4 2025, and $1.0 billion in Q3 2025.